Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Neurogene Inc. before investing.

In this article, we go over a few key elements for understanding Neurogene Inc.’s stock price such as:

• Neurogene Inc.’s current stock price and volume
• Why Neurogene Inc.’s stock price changed recently
• Upgrades and downgrades for NGNE from analysts
• NGNE’s stock price momentum as measured by its relative strength

About Neurogene Inc. (NGNE)

Before we jump into Neurogene Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Want to learn more about Neurogene Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Neurogene Inc..

Neurogene Inc.’s Stock Price as of Market Close

As of April 24, 2026, 4:00 PM, CST, Neurogene Inc.’s stock price was $27.030.

Neurogene Inc. is up 0.3% from its previous closing price of $26.950.

During the last market session, Neurogene Inc.’s stock traded between $26.370 and $27.560. Currently, there are approximately 22.08 million shares outstanding for Neurogene Inc..

Neurogene Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Neurogene Inc. Stock Price History

Neurogene Inc.’s (NGNE) price is currently up 34.08% so far this month.

During the month of April, Neurogene Inc.’s stock price has reached a high of $29.050 and a low of $19.131.

Over the last year, Neurogene Inc. has hit prices as high as $37.266 and as low as $11.770. Year to date, Neurogene Inc.’s stock is up 31.21%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Neurogene Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 24, 2026, there was 1 analyst who downgraded Neurogene Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Neurogene Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Neurogene Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Neurogene Inc. (NGNE) by visiting AAII Stock Evaluator.

Relative Price Strength of Neurogene Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 24, 2026, Neurogene Inc. has a weighted four-quarter relative price strength of 17.11%, which translates to a Momentum Score of 88 and is considered to be Very Strong.

Want to learn more about how Neurogene Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Neurogene Inc. Stock Price: Bottom Line

As of April 24, 2026, Neurogene Inc.’s stock price is $27.030, which is up 0.3% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Neurogene Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.